Literature DB >> 20673258

Understanding cost-effectiveness.

M D Zilberberg1, A F Shorr.   

Abstract

Healthcare delivery in the USA and abroad has changed dramatically over the last several decades. Along with the growth in diagnostic and therapeutic interventions, the costs of healthcare have escalated out of proportion relative to other aspects of the economy. This growth has fostered careful scrutiny of both the effectiveness and efficiency of healthcare delivery. Because of this emphasis on the economics of healthcare, physicians require an understanding not only of the efficacy and clinical utility of their interventions, but also of the relative value in an economic sense of their efforts. In other words, physicians in the modern era must now appreciate the concept of cost-effectiveness. Cost-effectiveness and cost-utility analyses are critical evaluative tools. Explicit data on comparative cost-effectiveness are useful for allocating the increasingly stretched healthcare resources. This article provides a primer for understanding the methods and applications of cost-effectiveness and cost-utility analyses.
© 2010 The Authors. Clinical Microbiology and Infection © 2010 European Society of Clinical Microbiology and Infectious Diseases.

Mesh:

Year:  2010        PMID: 20673258     DOI: 10.1111/j.1469-0691.2010.03331.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  6 in total

1.  Prophylactic Fixation Can Be Cost-effective in Preventing a Contralateral Bisphosphonate-associated Femur Fracture.

Authors:  Sam Y Jiang; David J Kaufman; Bonnie Y Chien; Michael Longoria; Ross Shachter; Julius A Bishop
Journal:  Clin Orthop Relat Res       Date:  2019-03       Impact factor: 4.176

2.  Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection.

Authors:  J M Pina; L Clotet; A Ferrer; M R Sala; P Garrido; L Salleras; A Domínguez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-12-13       Impact factor: 5.103

3.  Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.

Authors:  Yi-Wen Huang; Shun-Fa Yang; Yen-Po Yeh; Thomas Chang-Yao Tsao; Shih-Ming Tsao
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

4.  Use of Decision Analysis and Economic Evaluation in Breast Reconstruction: A Systematic Review.

Authors:  Gabriel Bouhadana; Tyler Safran; Becher Al-Halabi; Peter G Davison
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-04-27

5.  Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma.

Authors:  Zhuo-Miao Ye; Zi-Qing Tang; Zhe Xu; Qin Zhou; Huan Li
Journal:  Front Public Health       Date:  2022-07-22

Review 6.  Primary-level worker interventions for the care of people living with mental disorders and distress in low- and middle-income countries.

Authors:  Nadja van Ginneken; Weng Yee Chin; Yen Chian Lim; Amin Ussif; Rakesh Singh; Ujala Shahmalak; Marianna Purgato; Antonio Rojas-García; Eleonora Uphoff; Sarah McMullen; Hakan Safaralilo Foss; Ambika Thapa Pachya; Laleh Rashidian; Anna Borghesani; Nicholas Henschke; Lee-Yee Chong; Simon Lewin
Journal:  Cochrane Database Syst Rev       Date:  2021-08-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.